El-Adawy AH, Elkhawaga G, Elraheem SA, Mahfouz E. Impact of socioeconomic status on in-hospital outcome of patients with acute coronary syndrome in Egypt. Clin Med Res. 2017;6(6):164–72.

Article  Google Scholar 

World Health Organization. Cardiovascular diseases (CVDs). Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) [cited 2021 Dec 24].

Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management Part I. . IMayo Clin Proc. 2009;84(10):917–38. https://doi.org/10.1016/S0025-6196(11)60509-0 Elsevier.

Article  Google Scholar 

Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the american heart association. Circulation. 2019;139(10):e56–528.

Article  Google Scholar 

Leong DP, Joseph PG, McKee M, Anand SS, Teo KK, Schwalm JD, et al. Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease. Circ Res. 2017;121(6):695–710. https://doi.org/10.1161/CIRCRESAHA.117.311849.

CAS  Article  PubMed  Google Scholar 

Valgimigli M, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–60. https://doi.org/10.1093/eurheartj/ehx419.

Article  PubMed  Google Scholar 

Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012;72(16):2087–116.

CAS  Article  Google Scholar 

Husted S, Van Giezen JJJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27(4):259–74. https://doi.org/10.1111/j.1755-5922.2009.00096.x.

CAS  Article  PubMed  Google Scholar 

Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study. Circulation. 2009;120(25):2577–85. https://doi.org/10.1161/CIRCULATIONAHA.109.912550.

CAS  Article  PubMed  Google Scholar 

Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: The PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy. J Am Coll Cardiol. 2010;56(18):1456–62. https://doi.org/10.1016/j.jacc.2010.03.100.

CAS  Article  PubMed  Google Scholar 

Rosa GM, Bianco D, Valbusa A, Massobrio L, Chiarella F, Brunelli C. Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia. Expert Opin Drug Metab Toxicol. 2016;12(12):1491–502. https://doi.org/10.1080/17425255.2016.1244524.

CAS  Article  PubMed  Google Scholar 

Bach RG. 12 - Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. In: Brown DL, editor. Cardiac Intensive Care. 3rd ed. Philadelphia: Elsevier; 2019. p. 117–138.e7.

Chapter  Google Scholar 

Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(3):e18–114.

PubMed  Google Scholar 

Ticagrelor: Uses, Interactions, Mechanism of Action | DrugBank Online. Available from: https://go.drugbank.com/drugs/DB08816 [cited 2021 Dec 24]

Danchev N, Nikolova I. Generics—present and future. Biotechnol Biotechnol Equip. 2007;21(1):94–9.

Article  Google Scholar 

Generic Drugs: Questions & Answers | FDA. Available from: https://www.fda.gov/drugs/questions-answers/generic-drugs-questions-answers [cited 2021 Dec 24]

Lucas B. Impacts of Covid-19 on Inclusive Economic Growth in Middle-income Countries. K4D Helpdesk Report, 811. Brighton: Institute of Development Studies; 2020. Available from: https://opendocs.ids.ac.uk/opendocs/handle/20.500.12413/15310.

Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4(4):287–91. https://doi.org/10.1002/PST.185.

Article  Google Scholar 

Moore CG, Carter RE, Nietert PJ, Stewart PW. Recommendations for Planning Pilot Studies in Clinical and Translational Research. Clin Transl Sci. 2011;4(5):332. https://doi.org/10.1111/J.1752-8062.2011.00347.X.

Article  PubMed  PubMed Central  Google Scholar 

Platelet Aggregation Test: Purpose, Procedure, and Risks Available from: https://www.healthline.com/health/platelet-aggregation-test[cited 2021 Dec 24].

Teng R, Butler K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. Journal of Drug Assessment. 2013;2(1):30. https://doi.org/10.3109/21556660.2013.785413.

Article  PubMed  PubMed Central  Google Scholar 

Suresh K. An overview of randomization techniques: An unbiased assessment of outcome in clinical research. J Hum Reprod Sci. 2011;4(1):8. https://doi.org/10.4103/0974-1208.82352.

Article  PubMed  PubMed Central  Google Scholar 

McEwen BJ. The influence of diet and nutrients on platelet function. Semin Thromb Hemost. 2014;40(2):214–26 Thieme Medical Publishers.

Article  Google Scholar 

Makheja AN, Vanderhoek JY, Bailey JM. Effects of onion (Allium cepa) extract on platelet aggregation and thromboxane synthesis. Prostaglandins Med. 1979;2(6):413–24. https://doi.org/10.1055/s-0034-1365839.

CAS  Article  PubMed  Google Scholar 

Pamukcu B, Oflaz H, Onur I, Cimen A, Nisanci Y. Effect of cigarette smoking on platelet aggregation. Clin Appl Thromb Hemost. 2011;17(6):E175–80. https://doi.org/10.1177/1076029610394440.

Article  PubMed  Google Scholar 

Roskell NS, Samuel M, Noack H, Monz BU. Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace. 2013;15(6):787–97. https://doi.org/10.1093/europace/eut001.

Article  PubMed  PubMed Central  Google Scholar 

Wells G, Coyle D, Cameron C, Steiner S, Coyle K, Kelly S, Tang A, Healey J, Hsieh SC van BJ. Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2012 Apr 9. PMID: 24279001.

Cleophas TJ, Zwinderman AH. Statistics applied to clinical studies. 5th ed, Statistics Applied to Clinical Studies. Springer Netherlands; 2012 https://doi.org/10.1007/978-94-007-2863-9_228.

Jalali RK, Rasaily D. Generic Drug and Bioequivalence Studies. Pharm Med Trans Clin Res. 2018;1:327–39 Academic Press.

Article  Google Scholar 

Kaplan WA, Ritz LS, Vitello M, Wirtz VJ. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000–2010. Health Policy. 2012;106(3):211–24. https://doi.org/10.1016/j.healthpol.2012.04.015.

Article  PubMed  Google Scholar 

King DR, Kanavos P. Encouraging the use of generic medicines: Implications for transition economies. Croat Med J. 2002;43(4):462–9.

PubMed  Google Scholar 

McGavock H. Strategies to improve the cost effectiveness of general practitioner prescribing. 1997;(3):307-311 https://doi.org/10.2165/00019053-199712030-00003

Manzoli L, Flacco ME, Boccia S, D’Andrea E, Panic N, Marzuillo C, Siliquini R, Ricciardi W, Villari P, Ioannidis J. Generic versus brand-name drugs used in cardiovascular diseases. Eur J Epidemiol. 2016;31(4):351–68. https://doi.org/10.1007/s10654-015-0104-8 Epub 2015 Nov 30.

CAS  Article  PubMed  Google Scholar 

Alexopoulos D, Gkizas V, Patsilinakos S, Xanthopoulou I, Angelidis C, Anthopoulos P, Makris G, Perperis A, Karanikas S, Koutsogiannis N, Davlouros P. Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI. J Am Coll Cardiol. 2013;62(10):940–1. https://doi.org/10.1016/j.jacc.2013.05.021.

Article  PubMed  Google Scholar 

Collet C, Sotomi Y, Cavalcante R, Suwannasom P, Tenekecioglu E, Onuma Y, Serruys PW. Coronary stent thrombosis: what have we learned? J Thorac Dis. 2016;8(7):1398. https://doi.org/10.21037/jtd.2016.05.69.

Article  PubMed  PubMed Central  Google Scholar 

Bhatt DL. Prasugrel in clinical practice. N Engl J Med. 2009;361(10):940–2. https://doi.org/10.1056/NEJMp0806848.

CAS  Article  PubMed  Google Scholar 

Petricevic M, Jeppsson A, Kolh P. Optimal timing to discontinue ticagrelor before cardiac surgery: do we need additional evidence? Eur J Cardiothorac Surg. 2019;55(4):720 1 https://doi.org/10.1093/ejcts/ezy420

Hansson EC, Malm CJ, Hesse C, Hornestam B, Dellborg M, Rexius H, et al. Platelet function recovery after ticagrelor withdrawal in patients awaiting urgent coronary surgery. Eur J Cardiothorac Surg. 2017;51(4):633–7. https://doi.org/10.1093/ejcts/ezw373.

Article  PubMed  Google Scholar 

Jin L, Yu H, Dong T, Zhang B, Yan H, Liao H, Zou X. The prognostic value of ADP-induced platelet aggregation for bleeding complications in low-intermediate risk patients with acute coronary syndrome taking Clopidogrel after percutaneous coronary intervention. Heart Lung Circ. 2017;26(1):49–57. https://doi.org/10.1016/j.hlc.2016.05.113.

Article  PubMed  Google Scholar 

Reed GW, Kumar A, Guo J, Aranki S, Shekar P, Agnihotri A, Maree AO, McLean DS, Rosenfield K, Cannon CP. Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45 —a pilot study. Clin Cardiol. 2015;38(2):92–8. https://doi.org/10.1002/clc.22357.

Article  PubMed  PubMed Central  Google Scholar 

Chen IC, Lee CH, Fang CC, Chao TH, Cheng CL, Chen Y, Yu CL, Lin CC, Lin CY, Li YH, ESTATE Investigators. Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: a multicenter retrospective pilot study. J Chin Med Assoc. 2016 Oct 1;79(10):521–530 https://doi.org/10.1016/j.jcma.2016.02.010

Bonaca MP, Bhatt DL, Oude Ophuis T, Gabriel Steg P, Storey R, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Theroux P. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: A secondary analysis of the PEGASUS-TIMI 54 trial. JAMA Cardiology. 2016;1(4):425–32. https://doi.org/10.1001/jamacardio.2016.1017.

Article  PubMed  Google Scholar 

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O. Long-term use of Ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–800. https://doi.org/10.1056/NEJMoa1500857.

Article  PubMed  Google Scholar 

Krakowiak A, Kuleta J, Plech I, Zarębiński M, Wojciechowska M, Wretowski D, Cudnoch-Jędrzejewska A. Ticagrelor-related severe dyspnoea: mechanisms, characteristic features, differential diagnosis and treatment. Clin Med Insights: Case Rep. 2020. https://doi.org/10.1177/1179547620956634.

Article  Google Scholar